secwatch.observer — SEC 8-K summary
======================================

Issuer:     BELLICUM PHARMACEUTICALS, INC (—)
CIK:        0001358403
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0001539497-24-000590
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bellicum advances dissolution: all directors resign, Dave Maggio named CEO
--------------------------------------------------------------------------

- All five directors resigned effective Feb 23, 2024; Richard Fair remains sole director.
- CEO Richard Fair resigned; Dave Maggio appointed CEO effective same day.
- Consulting agreement with Fair extended to June 30, 2024.
- Stockholders approved dissolution plan on Feb 20, 2024; company winding down.
- Resignations not related to any disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/n3936_x24-8k.htm
  HTML page:      https://secwatch.observer/filing/0001539497-24-000590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer